How GLP-1 Medications Work

Y our body already makes a hormone that tells your brain you're full. GLP-1 medications work by mimicking it — turning up a signal that was always there but, for many people, never quite loud enough to override the drive to keep eating.

The hormone your gut already produces

GLP-1 stands for glucagon-like peptide-1. Your gut releases it naturally after you eat. Once in your bloodstream, it travels to your brain and signals that a meal is under way — slowing digestion, dialling back appetite, and helping regulate blood sugar levels by prompting the pancreas to release insulin when it's needed.

The response is real, but it's short-lived. The body breaks down natural GLP-1 within minutes. The medications used in medical weight loss are engineered versions that resist that breakdown, so the signal stays active for much longer — days, in the case of weekly injections.

What tirzepatide adds (the second pathway)

Some medications, including tirzepatide (Mounjaro), act on two receptors rather than one. In addition to the GLP-1 pathway, they also activate GIP (glucose-dependent insulinotropic polypeptide) — another gut hormone involved in appetite and fat metabolism. The combination appears to amplify the effect on satiety and weight loss compared with GLP-1 alone. Your clinician will recommend the right medication for your situation.

What the medication actually does

Three things happen when the medication is active:

Gastric emptying slows. Food moves out of your stomach more gradually. That means you feel fuller for longer after a meal and tend to reach for less at the next one.

Appetite and "food noise" drop. Many patients describe a noticeable quietening of the constant background chatter about food — the urge to snack, the fixation on what's next, the difficulty stopping once you've started. This is the mechanism working, not willpower suddenly improving.

Blood sugar is better regulated. More stable glucose levels reduce the sharp spikes and crashes that drive hunger and cravings, particularly in the afternoon.

The result: most people eat meaningfully less without the exhausting effort of white-knuckling their way through calorie restriction.

It's a tool, not a free pass

This is worth being direct about. GLP-1 medication makes a calorie deficit easier to sustain — it doesn't create the results on its own. What you do with the reduced appetite matters.

Protein intake becomes especially important. When the body is in a calorie deficit, it will draw on muscle as well as fat unless you give it a reason not to. Adequate protein, combined with resistance training, signals the body to preserve lean mass. That matters well beyond aesthetics: muscle is metabolically active tissue that supports long-term weight maintenance. (See our post on keeping muscle while losing weight for the full picture.)

Sleep and stress management remain in the picture too. Poor sleep elevates hunger hormones regardless of medication, and chronic stress can undermine the progress you're making.

How your dosing works

Your clinician will start you on a low dose and increase it gradually — a process called titration. The goal is to find the dose where you get meaningful appetite suppression with manageable side effects, most commonly mild nausea in the first few weeks as your body adjusts. Rushing the dose doesn't produce better results; gradual titration does.

Results vary. Most patients see steady, meaningful progress over months rather than weeks. Weight loss of this kind, at this pace, is more likely to be preserved long term.

Key takeaways

• GLP-1 is a natural gut hormone; the medications are long-acting versions that mimic it
• They work by reducing appetite, quietening food noise, slowing gastric emptying, and stabilising blood sugar
• Tirzepatide also acts on a second pathway (GIP), amplifying the effect
• The medication makes a calorie deficit easier — results still depend on protein intake, movement, and sleep
• Your clinician titrates the dose gradually; steady progress over months is the goal

*DRAFT — for clinical review before publication.*